Truist Financial Corp Has $2.33 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Truist Financial Corp cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 18.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,166 shares of the medical research company's stock after selling 8,644 shares during the period. Truist Financial Corp's holdings in Natera were worth $2,328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Natera by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company's stock valued at $334,388,000 after acquiring an additional 67,102 shares in the last quarter. Kynam Capital Management LP grew its stake in shares of Natera by 3.6% in the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company's stock valued at $132,912,000 after buying an additional 103,668 shares in the last quarter. RTW Investments LP increased its holdings in Natera by 1.5% in the third quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company's stock worth $117,341,000 after buying an additional 40,000 shares during the last quarter. Invesco Ltd. raised its position in Natera by 52.0% during the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock valued at $111,930,000 after acquiring an additional 865,404 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in Natera by 115.7% in the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company's stock valued at $73,203,000 after acquiring an additional 887,409 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

NASDAQ NTRA traded down $0.11 during midday trading on Thursday, hitting $95.55. The company had a trading volume of 3,188,199 shares, compared to its average volume of 1,424,082. The firm has a fifty day simple moving average of $92.00 and a two-hundred day simple moving average of $70.81. The stock has a market cap of $11.54 billion, a price-to-earnings ratio of -25.21 and a beta of 1.38. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Equities analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NTRA. Stephens restated an "overweight" rating and set a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a research report on Wednesday, May 1st. Raymond James lowered Natera from a "strong-buy" rating to an "outperform" rating and increased their price objective for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Piper Sandler boosted their target price on Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. Finally, Canaccord Genuity Group upped their target price on Natera from $87.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, February 29th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $86.40.

Insider Transactions at Natera

In related news, Director Herm Rosenman sold 93,901 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $69.37, for a total value of $6,513,912.37. Following the sale, the director now owns 61,685 shares of the company's stock, valued at approximately $4,279,088.45. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Natera news, Director Herm Rosenman sold 93,901 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $69.37, for a total transaction of $6,513,912.37. Following the completion of the transaction, the director now directly owns 61,685 shares in the company, valued at $4,279,088.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 9,326 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36. Following the completion of the transaction, the chief executive officer now owns 246,957 shares in the company, valued at $21,821,120.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 380,750 shares of company stock valued at $31,864,820. Corporate insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.